Research programme: lipocalin derivatives - Pieris Pharmaceuticals/sanofi-aventis/sanofi pasteur

Drug Profile

Research programme: lipocalin derivatives - Pieris Pharmaceuticals/sanofi-aventis/sanofi pasteur

Alternative Names: Anticalins - Pieris Pharmaceuticals/Sanofi

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Lipocalins; Proteins
  • Mechanism of Action Bacterial growth modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 01 Dec 2014 Preclinical trials in Undefined indication in Germany (unspecified route)
  • 10 Apr 2013 Pieris and Sanofi expands its collaboration to include a multi-specific Anticalin® programme
  • 30 Sep 2010 Early research in Undefined indication in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top